Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics (NQ: MRTX )

56.84 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 56.84
Bid (Size) 56.60 (12)
Ask (Size) 57.03 (10)
Prev. Close 56.84
Today's Range 56.84 - 56.84
52wk Range 27.30 - 101.30
Shares Outstanding 51,623,193
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Resilient Stocks with Massive Potential to Boost Your Wealth
These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life. 
Via InvestorPlace
These Three Biotech Stocks Are Trading At A Discount
Investors exposed to the biotech sector have seen mixed results this year. 
Via Talk Markets

Performance

YTD
+21.84%
+21.84%
1 Month
+1.99%
+1.99%
3 Month
+55.94%
+55.94%
6 Month
+45.86%
+45.86%
1 Year
-40.59%
-40.59%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks That Could Boom or Bust by 2025
Via InvestorPlace
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
From Kahn Swick & Foti, LLC
Via Business Wire
What 11 Analyst Ratings Have To Say About Mirati Therapeutics
Via Benzinga
3 No-Brainer Stocks to Buy With $500 Right Now
Via The Motley Fool
Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Is MIRATI THERAPEUTICS INC Ready to Break Out of Its Range?
Via Chartmill
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
Via InvestorPlace
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
Via Benzinga
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Via PressReach
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE
From Brodsky & Smith LLC
Via GlobeNewswire
Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
Via Benzinga
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
Via PressReach
MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
From Kahn Swick & Foti, LLC
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Shares of Tango Therapeutics Are Dropping Monday
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023
Via Benzinga
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasdaq - SP), Summit Materials (NYSE - SUM)
From Brodsky & Smith LLC
Via GlobeNewswire
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
Via Investor's Business Daily
Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics' $5B Deal
Via Benzinga
S&P 500, Nasdaq Set For Bleak Start To Week As Middle East Tensions Dampen Risk-On Mood: Earnings, Inflation Data In Focus
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.